Meet the Data: Conversations with Leading Experts on the Role of HCC and Immunotherapy
SIO Meet the Data Series: Explore the evolving landscape of hepatocellular carcinoma treatment in this four-part podcast series, featuring conversations with leading experts on the role of immunotherapy. This series features expert discussions highlighting emerging clinical trial evidence and addressing key knowledge gaps relevant to the implementation of these novel therapeutic regimens into clinical practice.

Episode 2: Local Therapy vs. Combination (Local + Systemic) Therapy Synopsis

How will the LEAP-012 and EMERALD-1 studies shape the future of liver cancer treatment? Experts Riad Salem and Stephen Chan analyze key differences in trial design, methodology, and clinical outcomes. Moderated by Lead Moderator Venkatesh Krishnasamy with Co-Moderator Sean Golden, the discussion explores how these pivotal studies may influence patient selection, treatment sequencing, and the real-world application of evolving care protocols.

Moderator:

• Venkatesh Krishnamsamy, MD | University of Alabama Birmingham

Co-Moderator:

• Sean Golden, MD | University of Wisconsin

Faculty:

• Riad Salem, MD, MBA | Northwestern University
• Stephen Chan, MBBS, MRCP, FHKCP, FHKAM, FRCP, FRCP, MD | Chinese University of Hong Kong

Resources

Riad Salem, MD, MBA

https://www.feinberg.northwestern.edu/faculty-profiles/az/profile.html?xid=17542

Stephen Chan, MBBS, MRCP, FHKCP, FHKAM, FRCP, FRCP, MD

https://www.med.cuhk.edu.hk/staff/professor-chan-lam-stephen

Emerald-Y90 Trial:

https://ascopubs.org/doi/10.1200/JCO.2025.43.16_suppl.TPS4221

LEAP-012 Trial:

https://www.thelancet.com/journals/lancet/article/PIIS0140-6736(24)02575-3/abstract

Disclaimer

This discussion is intended for healthcare professionals for educational purposes only. It does not constitute medical advice and should not replace individualized patient care decisions.